Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7994]

ESMO announces a scale to stratify the magnitude of clinical benefit of anti-cancer medicines

ESMO announces a scale to stratify the magnitude of clinical benefit of anti-cancer medicines

Deadly ovarian cancer outsmarts chemotherapy

Deadly ovarian cancer outsmarts chemotherapy

EHA 2015: DNMT3A R882 mutations promote chemoresistance and residual disease in AML

EHA 2015: DNMT3A R882 mutations promote chemoresistance and residual disease in AML

EHA 2015: First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia

EHA 2015: First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia

EHA 2015: Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression

EHA 2015: Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease...

EHA 2015: A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

EHA 2015: A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

EHA 2015: Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

EHA 2015: Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

EHA 2015: Does the patient with myelofibrosis feel better through pacritinib?

EHA 2015: Does the patient with myelofibrosis feel better through pacritinib?

NICE reject enzalutamide for advanced prostate cancer before chemotherapy

NICE reject enzalutamide for advanced prostate cancer before chemotherapy

Mayo clinic to study 10,000 patients for drug-gene safety

Mayo clinic to study 10,000 patients for drug-gene safety

More from ecancer